In this issue of Clinical Cancer Research, Kelloff et al. (1) present an overview on cancer chemoprevention drug development. This state-of-the-science article represents the collective input from cancer prevention scientists assembled under the auspices of the AACR. This review complements and extends the discussion in the landmark special article on the treatment and prevention of intraepithelial neoplasms published in Clinical Cancer Research in February 2002 (2). Both of these articles provide background information on the mechanisms of carcinogenesis and cancer progression that are relevant to chemoprevention strategies.

The Editors encourage investigators to submit their new work in clinical cancer prevention to Clinical Cancer Research, especially if it was presented at the annual AACR meeting or the AACR Frontiers in Cancer Prevention Research meeting. Because the focus of Clinical Cancer Research is on innovative clinical research and translational research that bridges the laboratory and the clinic, we prefer reports of relevant human biomarker studies, carefully conducted phase I and phase II chemoprevention trials, and larger phase III interventions that have robust statistical design (see Instructions for Authors). Preclinical research or studies using animal models will be considered but should have evident relevance to human cancer prevention interventions.

1
Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia (IEN) and cancer: a plan to move forward. Clin Cancer Res; 2006.
2
O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
Clin Cancer Res
2002
;
8
:
314
–46.